南京大美生物制药

Nanjing Damei Biological Pharmaceutical is a China-based biotechnology company dedicated to the research and development of next-generation cell therapies, with a primary focus on chimeric antigen receptor T-cell (CAR-T) treatments for solid tumors. The company's pipeline includes candidates targeting Glypican-3 (GPC3) for hepatocellular carcinoma and Claudin 18.2 for gastric and pancreatic cancers. Headquartered in the Nanjing Jiangbei New Area, the firm leverages advanced genetic engineering and cell manufacturing platforms to improve the persistence and infiltration of CAR-T cells in the tumor microenvironment. Nanjing Damei aims to translate cutting-edge immunological research into effective clinical solutions for patients with refractory cancers. The company is currently advancing several programs through early-stage clinical trials and preclinical validation.